Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06462612 · ClinicalTrials.gov registry record · Phase 3

Study of Lumateperone in the Treatment of Patients With Bipolar Mania

A Phase 3 study of Bipolar Disorder, Manic, sponsored by Intra-Cellular Therapies.

Recruiting
Registry status
Phase 3
Development phase
350
Enrollment target
20
Study locations

NCT06462612 is a Phase 3 study of Bipolar Disorder, Manic that is actively recruiting participants, run by Intra-Cellular Therapies. The registered enrollment target is 350 participants. The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06462612, a Phase 3 study of Bipolar Disorder, Manic, is actively recruiting participants, sponsored by Intra-Cellular Therapies.

RECRUITING
Registry status
Phase 3
Development phase
350 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Lumateperone

Study Locations (20)

Florida

  • Clinical Site - Hialeah
  • Clinical Site - Miami
  • Clinical Site - Miami
  • Clinical Site - Miami
  • Clinical Site - Miami Lakes
  • Clinical Site - Miami Lakes
  • Clinical Site - Tampa
  • Clinical Site - West Palm Beach

California

  • Clinical Site - Anaheim
  • Clinical Site - Cerritos
  • Clinical Site - Orange
  • Clinical Site - Torrance

Arkansas

  • Clinical Site - Bentonville
  • Clinical Site - Little Rock

Georgia

  • Clinical Site - Atlanta
  • Clinical Site - Stockbridge

Illinois

  • Clinical Site - Chicago
  • Clinical Site - Chicago

Maryland

  • Clinical Site - Gaithersburg

New York

  • Clinical Site - Glen Oaks

Trial Details

FieldValue
Enrollment Target 350 participants
Start Date 2024-07-17
Est. Completion 2026-06
Phase Phase 3

Sponsor

Intra-Cellular Therapies

37 total trials

What the Registry Record Tells You About NCT06462612

The ClinicalTrials.gov registry entry for NCT06462612 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Disorder, Manic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06462612 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06462612 about?

NCT06462612 is a clinical study titled "Study of Lumateperone in the Treatment of Patients With Bipolar Mania". This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with or without psychotic symptoms, according to criteria of the Diagnostic ...

What is the current status of trial NCT06462612?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2024-07-17. Estimated completion is 2026-06.

What conditions does trial NCT06462612 study?

This clinical trial studies the following conditions: Bipolar Disorder, Manic.

What interventions are being tested in trial NCT06462612?

The interventions under investigation include: Placebo (DRUG), Lumateperone (DRUG).

Who is sponsoring clinical trial NCT06462612?

This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06462612 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Disorder, Manic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.